GALT
(NASDAQ)
2.54
-0.0700   (-2.68%)
Pre-market: .00 -2.54 (-100.00%)
Volume (24h) Market Cap. Day Range 52w Range
125.42K 144.98M 2.48 - 2.62 1.50 - 4.50
Oct-12-20 12:11PM New Strong Sell Stocks for October 12thZacks
Oct-06-20 07:30PM These 2 Penny Stocks Could Quadruple (Or More), Says H.C. WainwrightTipRanks
Sep-29-20 04:00PM Galectin Therapeutics Investor Conference Call and Webinar Taking Place TodayGlobeNewswire
12:52PM Implied Volatility Surging for Galectin Therapeutics (GALT) Stock OptionsZacks
Sep-22-20 12:04PM Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020GlobeNewswire
Sep-10-20 12:00PM Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020GlobeNewswire
Sep-09-20 03:46PM Insider Buys Galectin Therapeutics StockBenzinga
Sep-02-20 12:00PM Galectin Therapeutics Appoints Joel Lewis as Chief Executive OfficerGlobeNewswire
Aug-10-20 12:00PM Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business UpdateGlobeNewswire
Aug-03-20 04:48PM Is Galectin Therapeutics, Inc.'s (NASDAQ:GALT) Shareholder Ownership Skewed Towards Insiders?Simply Wall St.
Jun-30-20 01:05PM UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH CirrhosisGlobeNewswire
12:00PM Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH CirrhosisGlobeNewswire
Jun-05-20 01:48AM Hedge Funds Are Souring On Galectin Therapeutics Inc. (GALT)Insider Monkey
May-22-20 12:17PM Galectin Therapeutics' Shares March Higher, Can It Continue?Zacks
May-11-20 12:00PM Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business UpdateGlobeNewswire
May-04-20 12:37PM Companies Like Galectin Therapeutics (NASDAQ:GALT) Are In A Position To Invest In GrowthSimply Wall St.
Apr-30-20 01:00PM Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH CirrhosisGlobeNewswire
Apr-02-20 12:04PM Galectin Therapeutics Update on the Impact of COVID-19GlobeNewswire
Mar-16-20 12:00PM Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business UpdateGlobeNewswire
Feb-20-20 01:00PM Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical OfficerGlobeNewswire
Feb-05-20 09:11PM 13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion MarketBenzinga
Feb-04-20 01:04PM Are Insiders Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Stock?Simply Wall St.
01:00PM Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020GlobeNewswire
Dec-20-19 11:38PM Is Galectin Therapeutics Inc. (GALT) Going to Burn These Hedge Funds?Insider Monkey
Dec-09-19 01:00PM Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in GastroenterologyGlobeNewswire
Dec-05-19 05:06PM Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH CirrhosisGlobeNewswire
Nov-26-19 01:00PM Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of StockholdersGlobeNewswire
Nov-18-19 09:10PM Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) SummitGlobeNewswire
Nov-12-19 01:00PM Galectin Therapeutics Reports Q3 2019 Financial ResultsGlobeNewswire
Nov-11-19 02:47PM Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver FibrosisGlobeNewswire
Nov-05-19 01:00PM Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver MeetingGlobeNewswire
Oct-28-19 12:39PM We're Not Worried About Galectin Therapeutics's (NASDAQ:GALT) Cash BurnSimply Wall St.
Sep-17-19 12:00PM Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer ImmunotherapyGlobeNewswire
Sep-11-19 02:13PM Small Drug Stock Outlook: Innovation Holds the Key to GrowthZacks
Aug-27-19 07:21PM Need To Know: Galectin Therapeutics, Inc. (NASDAQ:GALT) Insiders Have Been Buying SharesSimply Wall St.
02:21PM New Strong Buy Stocks for August 27thZacks
Aug-27-19 01:00PM FibroGen (FGEN) Catches Eye: Stock Jumps 7.4%Zacks
Aug-09-19 12:00PM Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business UpdateGlobeNewswire
Aug-07-19 03:20PM Bausch (BHC) Misses on Q2 Earnings & Sales, Raises ViewZacks
03:15PM Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/YZacks
Aug-06-19 02:51PM Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 GuidanceZacks
Aug-05-19 12:05PM Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDAGlobeNewswire
May-28-19 01:05PM Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant ExerciseGlobeNewswire
May-27-19 12:44PM What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s (NASDAQ:GALT)?Simply Wall St.
May-23-19 09:30PM Galectin Therapeutics Reports Alternate Price of Common Stock in Rights OfferingGlobeNewswire
May-10-19 12:05PM Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019GlobeNewswire
12:00PM Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business UpdateGlobeNewswire
Apr-15-19 12:00PM Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration StatementGlobeNewswire
Apr-02-19 12:00PM Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences ConferenceGlobeNewswire
Mar-22-19 02:19PM Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular BiologyGlobeNewswire
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Cap:    |  Volume (24h):